Callouts & quotes from 10,384+ activist slides

"Here's the time line and the value opportunity. So currently, we're in that feasibility study stage focused on RPM, just finished our last round of drilling. Watch the news flow in the coming weeks as drill results start to come in and then get this resource update before the end of the year. Concurrently, we have the next level of metallurgical test work happening now. Everything converging on delivering this feasibility study for RPM by the end of 2025. All of our resources are going towards that. — Nova CEO, Sept 30, 2024"

"One individual report can make a difference. Many drug withdrawals began with one clinical report that initiated further investigation...a single report ultimately led to the removal of terfenadine from the market. This report potentially saved many lives and led to a better understanding of the mechanism involved in causing torsades de pointes. Almost all drugs are now evaluated prior to being released on the market for their potential to induce cardiac arrhythmias, also as a result of this single case report. — FDA website"

"The current CEO is Peter Chapman. He doesn’t know quantum computation at all. And he’s a salesman at the same time. This, in my opinion, is a very dangerous combination because I have heard him say things that are just completely wrong. Outside IonQ, and I’m sure probably even inside IonQ because I know technical people at IonQ, and I understand that they’re worried. Outside IonQ, people laugh at the kinds of things that Peter Chapman says. — Leading quantum computing researcher who has published papers with IonQ’s founders"

"“The downtime was 20%. The good news is they were right across the bridge, and the technician who would fix it actually lived up the street in San Mateo from where we were.” — Bristol Meyers expert #2; “It's got a lot of fluidics, and high-end FACS machines have the same problem. If you don't know how to take care of them, they become a very expensive doorstop very fast.” — Bristol Meyers expert #2; “We wouldn't let the average scientist walk up and use these machines because they're too complex.” — Bristol Meyers expert #2"

"The demand for prospective participants thus increased in geometric progression while the number of potential investors available in a given community or geographical area remained relatively constant. . . The exhaustion of prospects results from over-saturation . . . [T]he imposition of an inappropriate statewide quota did not negate the endless chain representation, nor did it prevent the chain from soon reaching the saturation point in a number of local areas. — In re Koscot Interplanetary, Inc. (86 F.T.C. 1114, 1132-33)"

""What typically happens, the pattern is, we go into a city, we’ll open up large learning centers first, fifteen hundred square meter ones. Then we’ll open up five hundred to one thousand square meter ones in the, in the second sort of ring, you know second set of large schools." — Louis Hsieh. "What [opening 81 learning centers in Q3 2012] should tell you guys is that our business is so strong in one-on-one and kids that we’re opening up a lot more centers than we normally would." — Louis Hsieh to an investor in June 2012."

"“CSIM believes that the board is typically best positioned to determine its leadership structure. Therefore, CSIM will typically not support proposals requiring the separation of these roles unless certain circumstances are in place.” — Charles Schwab Investment Management. “We will generally vote for proposals looking to separate the CEO and Chairman roles unless the company has governance structures in place that can satisfactorily counterbalance a combined chairman and CEO/ president post.” — JP Morgan Asset Management."

"“Actually, early on, it was substantial, especially for NGS. They made a really big splash, and I think that their low prices compelled a heck of a lot of even tightly regulated clinical labs to switch over to them. But, of course, you don’t necessarily recognize low consistency in the short term. You recognize that after multiple years. At least at the time that I left IDT, the team was having a substantial amount of success at winning back the customers they had lost several years before.” — IDT ex-regional sales manager"

""This alliance is a critical addition to our industrial asset management capabilities as we continue to strategically invest for growth by delivering integrated APM solutions for our energy and industrial customers. We share the same strategic vision of combining critical equipment engineering with digital analytics, and Augury also has broad technology and skillsets that complement our existing offering to improve efficiencies, productivity and operational excellence." — Lorenzo Simonelli, chairman and CEO at Baker Hughes"

""I'm proud to announce that TaskUs is profitable and on a $35 million revenue run rate. We've doubled revenue and headcount in the past five months, and we plan to triple our current revenue and headcount by the end of 2016." — PR, June 2015; "They've got 1,500 employees between Santa Monica and The Philippines, and closed out 2014 by doing $15 million in top-line revenue, increasing from the $6 million they did in 2013." — Leveling Up Interview; "Revenue was $8 million in 2014" — Spruce Point Interview of Former Executive"

"The Audit Committee and the Board have determined that it would be in the best interests of the Company to make changes in the leadership for the oversight and control of its financial operations to correct the "tone at the top" and ensure it is consistent with the Board's commitment to maintaining strong corporate governance. The Company will enhance the accounting organization, both by adding personnel to that function and by increasing training for all members of the organization. — Mettler-Toledo (2004 10-Q disclosure)"

"We note that senior secured loans appear to have grown to 80% of total loans held for investment at amortized cost, 18.6% of total loans held for investment, and 6.9% of total loans as of June 30, 2024. In future filings, please revise your disclosures, in an appropriate location, to provide an expanded discussion of your senior secured loans that more fully describes the borrower population, underlying collateral characteristics, and typical duration of the loans. — SEC Comment Letter to SOFI Technologies, Sept. 19, 2024"

"Search for a new director did not commence until after Elliott launched its proxy contest. Mr. Hess replaced Sir Martin Sorrell, who only attended 63% of Arconic's board meetings in 2016 – this would have resulted in an automatic AGAINST recommendation by major proxy advisors. Mr. Hess decided to join the Board after Elliott launched proxy contest and promptly endorsed a failed CEO, which Sir Sorrell has a significant stake, was compensated for Dr. Kleinfeld's wasteful and exorbitantly expensive Jetsons marketing campaign"

""The process is very sensitive," says Anca Gavris, the Millville plant manager and its first employee. "Everything needs to be to perfection." — Bloomberg, July 31, 2019. "We are also subject to the risk that as we continue to expand, our trade secrets, confidential information and the know-how related to our oat base and other proprietary products could be leaked, intentionally or unintentionally, misappropriated or stolen, which could have an adverse effect on our business and results of operations." — Prospectus, p. 31"

"“Because of the cost, people are going to start shifting gears, and they're going to be changing to a different pump because it's not sustainable for a transplant center, and I understand that TransMedics, they're going to tell you, this is going to be covered by Medicare and by private insurance and yadda, yadda. The reality is that this is going to drive the healthcare cost - you already know that the healthcare in America is destroyed - so this is going to kill the healthcare system.” — Transplant surgeon at Vanderbilt"

""If you look at where search comes from on the AOL properties, majority of it comes from the homepage client and from AOL.com." — CEO Tim Armstrong, 2Q10 conference call, 8/4/10; "... AOL's search business is intimately linked to the Access business. Content isn't driving search – it's people who use AOL software. Current and former Access and AIM users. AOL tried a lot of things to get more users from other sites to use Search, but nothing worked, it was fairly disappointing ...." — Former senior AOL employee, March 2012"

"“The turnaround would be astonishing in any industry, but especially in the beverage-marketing business, where short-lived brands are depressingly common... I posed those questions to Triarc’s top executives: chairman and majority owner Nelson Peltz, CEO Mike Weinstein... There is a vital interplay between the challenge a brand faces and the culture of the corporation that owns it. When brand and culture fall out of alignment, both brand and corporate owner are likely to suffer...” — John Deighton, Harvard Business Review"

""Moody's believes a sustained improvement in Olive Garden's earnings and same store sales performance over the intermediate term could be challenging given soft consumer spending and competitive pressures. This is of particular concern given that Olive Garden will comprise the substantial majority of Darden's consolidated earnings and be the key credit support for the company, which will be less diversified and smaller in scale post the divestiture of Red Lobster." — Bill Fahy, Moody's Senior Credit Officer, May 16, 2014"

"The LICAT guideline establishes standards, using a risk-based approach, for measuring specific life insurer risks and for aggregating the results to calculate the amount of a life insurer's regulatory "required capital" to support these risks. The amount of capital targeted by the LICAT is meant to allow an insurer to survive a 1-in-200-year adverse event. LICAT also defines which components of the insurer's capital structure can be counted as "available capital" to satisfy the "required capital" benchmark. — Mr. Rehbeli"

""Moody's believes a sustained improvement in Olive Garden's earnings and same store sales performance over the intermediate term could be challenging given soft consumer spending and competitive pressures. This is of particular concern given that Olive Garden will comprise the substantial majority of Darden's consolidated earnings and be the key credit support for the company, which will be less diversified and smaller in scale post the divestiture of Red Lobster." — Bill Fahy, Moody's Senior Credit Officer, May 16, 2014"

"Our inspection revealed that your firm knew that the device’s transmission limit, which was explained in the previous section, was resulting in data not being transmitted. Records reviewed during our inspection indicate that your firm has been aware of customer complaints related to this issue since at least 2019. Specifically, our inspection found a significant number of complaints regarding this issue, which revealed two deaths as well as significant arrythmias that were not reported to physicians. — FDA Warning Letter"

"“Indicative of the strength within our portfolio is the performance of our 50 most productive United States centers. These properties generated average sales per square foot of approximately $648. Not only do these 50 centers produce tremendous sales per square foot, they also represent approximately 50% of our total mall NOI. This is one more example of the quality of our portfolio, and quality will be more important than ever as we move forward in 2008 and 2009.” — John Bucksbaum, Chairman and Former CEO, July 31, 2008"

"“Our SORT business has been rapidly growing as a result of privacy trends, I mentioned before.” — Perion CEO (Q3 2022); “This is why we believe SORT will continue to be a major contributor to revenue and EBITDA.” — Perion CEO (Q1 2023); “Another thing we added into the cost, we’re not charging for it, it’s built into the cost... We’re offering different solution for targeting. It’s called SORT. At this point, we are not charging for it. We are offering it to our customers.” — Perion CEO (Needham Conference, May 17, 2023)"

"“I just saw somebody today and the kid already has diabetes...we were talking about what she would have to do as far as monitoring and everything [if on Vykat]...and she’s like, oh, I had no idea...she said, well, could it make it worse...and I said, absolutely...it’s being downplayed...having sat through I don’t know how many informational sessions before and after it was approved - it feels like propaganda...I really feel they’re downplaying side effects.” — KOL in the PWS field; involved with Soleno’s clinical program"

""Evaluation of the char was not within the scope of the project; however, it is considered to be unlikely to have such high value when produced from a non-coking coal such as the Powder River Basin (PRB) coal used in this study." — Ramaco Carbon Technical Report (March 2023). "guilty of conversion, unauthorized use of partnership funds for non-partnership purposes, usurping a partnership opportunity and of violating their fiduciary responsibilities to the partnerships." — Bankruptcy Court ruling regarding Randall Atkins."

""So you've just seen the acquisition of PCC that's underway by Warren Buffet's Berkshire Hathaway. And he paid for a business that is having $10 billion of revenue, whereas $6 billion of those $10 billion are having a full overlap with us." — Dr. Klaus Kleinfeld, October 8, 2015; "So, I mean, the most natural competitor when you go to aerospace is PCC right? And the aerospace business, I mean, pretty much we are catering in all of these businesses that PCC also caters to, right?" — Dr. Klaus Kleinfeld, September 8, 2015"

""We've conducted dozens of focus groups across the country listening to hundreds of agents, home buyers and home sellers, learning why they were so dissatisfied with the legacy offerings and what they hope for in a better residential portal. We heard loud and clear that brokers, agents, sellers, buyers and investors all dislike, real estate portals that use agents listings as baked to drill in homebuyers and then sell them off to other agents as leads with exorbitant commission splits." — CoStar CEO, Q4'23 Earnings Call"

""it's supposed to go to the OPO to reallocate the liver...but as soon as TransMedics finds out, they have quite the list of backups, they are already calling other surgeons and being like, could you potentially use this liver?...a lot of these conversations [are] happening...I'm not exactly sure what is said...I just know that these phone calls are being made and then it's...coming back into the OR and being like, this particular surgeon could use this liver. Why don't you call them?" — Former TransMedics OCS specialist"

"“... Patch provides general branding for local businesses, but this is not what most customers want. Local advertisers want to see the impact of their spend, and generally prefer pay-for-performance advertising...” — Former Patch ad manager, March 2012; “... our local advertisers are sophisticated and smart. They want to know about metrics and performance. They’re not going to pay a $35 CPM to reach twelve people, which is unfortunately what they would have been paying at times....” — Former Patch ad manager, March 2012"

"I was very critical, and they didn't want to talk about the side effects, which I insisted on...they didn't even tell us that those papers were being prepared or published...there were complications...they develop hairiness...they develop diabetes...they develop edema...we had to give diuretics; co-authors were not even informed about the existence of this papers; it's bizarre...[redacted] would have recruited a big number, yet [redacted's] name is not on the paper...very odd...it was very odd... — Trial investigator #2"

"“we’re almost 10 weeks in – I haven’t noticed any ‘improvements’...if I don’t see improvements at week 15/20, I may stop it...why take a medicine that’s not helping?”; “still titrating...the focus on food is the same...praying it gets better as we go along”; “no behavior changes that I noticed...we made it week 8...but stopped due the edema”; “she still wants many snacks...I do t [sic] know how much more I can tolerate”; “my granddaughter is very similar...always discussing food...5 months on Vykat...” — Facebook groups"

"So as we go public here through this SPAC, we will be very well-capitalized to be able to pursue that M&A strategy. So we'll end this transaction debt-free with $205 million of capital on our balance sheet. When we went out to do our pipe raise, we started at $50 million pipe. It was upsized in the second day to $100 million and then upsized again to $150 million, and we are still 2x oversubscribed for that pipe. And so that will give us a lot of ammo to be able to go and pursue our strategy — CEO Gateway Conf Sept 2020"

""this issue from our perspective is an attempt to sow confusion where none exists" — Burford Management; "so we don't believe that these [are] aggressive marks." — Burford Management; "So I think that the suggestion in the report that there's anything untoward or mysterious there is not a well-founded." — Burford Management; "we provide IFRS compliant financials," — Burford Management; "Burford's accounting and financial reporting is transparent, appropriate and has been consistent for many years." — Burford Management"

""The uLab software is advancing very rapidly. They are developing attachments that will allow an orthodontist to do the most comprehensive cases by just using clear aligners." — Dental Consultant; "With uLab, I can now do combo cases. Wires and brackets are often much more efficient for certain necessary movements. When I am doing combo cases, I am completing them much faster. I would guess that I am completing cases 6 months faster." — Orthodontist; "uLab has a huge waitlist to use [the software]." — Dental Consultant"

"The manner in which Dr. Kleinfeld chose to bolster Alcoa’s balance sheet, selling equity at the bottom, amounted to a bailout of existing shareholders – one ironically done at a significant opportunity cost to those investors with the misfortune of having participated. Had those participating investors invested in the Company’s self-selected proxy peers instead of placing their capital under the stewardship of Dr. Kleinfeld, they would have generated a return approximately 4x that realized on their investment in Alcoa."

""Management is not particularly disciplined and tends to bid aggressively when it wants an asset." — Former senior employee; "We could have bought a particular asset for 7x EBITDA, but Matt was not interested. When Matt heard that a competitor was interested to buy the asset, suddenly he wanted to own it, and we ended up paying a lot more. There is no real process or discipline around M&A." — Former senior employee; "Dye and Durham keeps paying irrational prices for acquisitions where we compete." — CEO of a competitor"

"Our residual assets are subordinate to investors' interests, and their values are subject to credit, prepayment and interest rate risks on the transferred financial assets. The investors and the securitization trusts have no recourse to our other assets for failure of debtors to pay when due. In computing gains and losses on securitizations, we use the same 8% discount rate for the fair value calculation of residual assets, which is determined based on a review of comparable market transactions. — HASI 2021 10-K, p. 96"

""The Group also enters into nonmonetary transactions to exchange online broadcasting rights of licensed copyrights with other online video broadcasting companies from time to time. The exchanged licensed copyrights provide rights for each party to broadcast the licensed copyrights received on its own website only. Each transferring party retains the right to continue broadcasting the exclusive content on its own website and/or sublicense the rights to the content it surrendered in the exchange." — IQ 2018 20-F, p. F-24"

""I can't tell what's different about them." — Current Joyn executive; "I think both companies were always looking jealously at each other or trying to one-up each other. But I don't think there's a large differentiation between the two companies per se besides that historical philosophy... they're more similar to each other than they are different." — Former director level employee; "Wow, it's like Zymergen too here. All the same stuff is happening, except it's happening even faster at Ginkgo." — Former Ginkgo employee"

"If you are starting from scratch, Shopify is the one I would probably start with. Its easy to set up and its more than enough for the first 24-36 months in business. The only reason I would say Lightspeed is because it's a solution you can grow into versus vs. Shopify which is a solution you grow out of. And that is because Shopify just doesn't cater to complex retailers. You almost never see a 20, 30, 50 location retail business using Shopify. There are much better tactics with Lightspeed. — Former Lightspeed Employee"

""But looking forward, we want to reiterate our commitment to long-term growth of 25% on the top line." — Fmr. CEO Zollars, Vocera 2012 Conf Call; "We, however, have not changed our view of the long-term gross margin target of 70%, since we believe all the same drivers remain in place." — Fmr. CEO Zollars, Vocera Q1 2013 Conf Call; "And we've published that our target model at a $200 million run rate, we believe we can get to a 68% gross margin and a 20% adjusted EBITDA margin." — CEO Lang, Vocera JPM Conf, Jan 12, 2017"

"“Some investors are protesting that Darden’s idea of ‘direct engagement’ amounts to returning the phone calls of analysts and investors who agree with its strategy while ignoring calls from dissenters. ‘They’ve got a history of only engaging with investors and analysts who are supportive of their views,’ said one Darden shareholder, who declined to give his name for fear of retribution from the company. ‘If the board is so convinced [a Red Lobster spinoff] is such a great idea, then put it to a vote.’” — New York Post"

"I know all the pros and cons of this company...We began working on the instrument itself in 2016...I cannot say that I love it...The people who have a lot of hesitation on the instrument are the ones that require training...we had to run our own software for the processes and workflows that we wanted to run...there were errors that were showing up, and it was not clear how to identify what they were related to...these are definitely challenges. Absolutely, I couldn't say that I love the instrument. — Amgen employee #1"

""It's not like other instruments that are fully developed. It's kind of like a beta version." — AbbVie scientist; "What is bothering me is that I have to manually process all the images. That's a major headache and the time-consuming part...It's tedious. You have to babysit it." — AbbVie scientist; "Like once every five runs." — AbbVie scientist; "I think it's due to the limitation of the assay or the screening it can do." — AbbVie scientist; "It's not providing a ready-to-use assay for other uses." — AbbVie scientist"

"On December 4, 2012 the freenet.de GmbH (whose sole shareholder is the company), closed a contract with Media Ventures GmbH, Cologne, selling all of its freeXmedia GmbH shares. This transaction was carried on January 1, 2013. For the sale, a purchase price of T€ 4,080 was agreed. The amount was split in T€ 2,080 thousand payable in cash and the remaining T€ 2,000 payable until December 31, 2014 through offset with services from a media contract, which freenet AG concluded with the buyer. — freenet's 2012 Annual Report"

""Trian has chosen this path [a proxy contest] with the potential to disrupt our Company at a key stage of execution against our plan" — DuPont Press Release, 1/8/15; "Trian’s presence on the Board will create substantial risk in Heinz’s ability to deliver value to all shareholders" — Heinz (6/06); "I said to another CEO that if I were to form a board today, Nelson [Peltz] would be one of the first directors I’d ask to serve... [Trian’s] team had good questions and good suggestions." — Bill Johnson, CEO Magazine (3/08)"

""Trian has chosen this path [a proxy contest] with the potential to disrupt our Company at a key stage of execution against our plan" — DuPont Press Release, 1/8/15; "Trian's presence on the Board will create substantial risk in Heinz's ability to deliver value to all shareholders" — Heinz (6/06); "I said to another CEO that if I were to form a board today, Nelson [Peltz] would be one of the first directors I'd ask to serve... [Trian's] team had good questions and good suggestions." — Bill Johnson, CEO Magazine (3/08)"

""If you're looking for good value for producing a low-cost precursor for carbon material, I think you'd be hard-pressed to find a better place to do that than the Powder River Basin," — Charlie Atkins. "According to court documents and statements made in court, Charles Agee Atkins, of Chapel Hill, controlled and operated several risk consulting businesses... Atkins underreported the income that he received from these businesses on his tax returns, causing a tax loss of more than $380,000 to the IRS." — Court Documents"

"“To be brutally honest, they really didn't have much impact as we thought they would [when they launched]...they really didn't have much impact on us, and our business continued to grow, like 20% to 30% every year, which is beating the market in general on average, and we are still a market leader. So, we haven't really seen them as a big threat as we thought they would be...we haven't seen much of an impact, and we don't see them as a major threat for business anymore.” — Executive at Genscript, key Twist competitor"

"For example, if an analyst tried to verify market share data for handsets in China and surveyed 1000's of people in the streets of Beijing or Shanghai, they might find results that would show 65% of users have Samsung-branded phones while 35% have Apple's iPhone. One might conclude from this faulty sampling methodology that there is no way that Huawei, ZTE, Lenovo, or Xiaomi would have the kind of market share that actually exists. — NQ "Response to J Capital Report Titled, ‘NQ: Not At Any Price,’” August, 2013, p.2."

""We believe our brand is one of the most important long term differentiators." — CEO Dudum on Q1 2022 Earnings Call; "Our CEO, our leadership never really seemed that concerned with those direct competitors. The, the viewpoint was that there's plenty of space in the market. We're gonna win the brand battle...Their younger customer base may become a little more price conscious and realize, hey, this is a great brand, but they're not really offering anything special." — Spruce Point Interview With Former HIMS Executive"

"One bad thing about Stryker - a long term assessment - this is the issue. You need enough people that understand all of this. Stryker's executive team has no one from R&D at the table. Internal innovation has not delivered a huge amount of value. Taking something internal and taking it to the market, that's not Stryker's strength. In our view, innovative companies deserve a premium multiple, while those that can't innovate and are dependent on inorganic growth do not deserve a premium — Former senior Stryker employee"

"Research and development expenses for the year ended December 31, 2024, were $111 million, an increase of $2 million as compared to the same period in 2023. The increase was primarily driven by $17 million from the acquisition of Snap One, which was partially offset by $15 million from lower third-party spend and personnel costs. Key drivers of the lower spend relate to optimization efforts and a realignment of IT resources towards maintenance projects within the Products and Solutions segment. — REZI 2024 Disclosure"

"That is very concerning. We use this drug to make blood sugars go up...we're the biggest referral center for hyperinsulinism in little babies...we also talked about it being a little surprising because we weren't expecting this to be the type of drug that would be used in this condition...people seem to say, okay, we'll see...certainly at the meeting, I didn't go to any specific talks about this, but no one talked about it. I don't think it was a big enough topic to make the headlines. — PWS endocrinologist #2 (CHOP)"

"In this patient population, especially, it doesn't take much to make them diabetic or certainly hyperglycemic...and no surprise, given this mechanism of action. No surprise...and importantly, some patients get ketoacidotic because the insulin suppression is so potent at these doses that you essentially render the patient to be type-one diabetic, which increases the risk of ketoacidosis, which could be potentially lethal in wide use being in this context. — Endocrinologist; academic and community hospital affiliations"

""TCO reported a solid start to the year, with a number of key metrics accelerating sharply..." — KeyBanc; "We noticed comp center measures, including NOI and sales per sq. ft. did exceedingly well..." — Bank of America Merrill Lynch; "Overall we would characterize this evening's earnings report as better than expected for TCO..." — Evercore ISI; "Despite retail headwinds, [1]Q18 tenant sales per square foot grew 12.4% y-o-y..." — Jefferies; "TCO reported results ahead of expectations with strong SS NOI..." — Boenning"

""On 2 January 2019 the Group acquired 89,8% holding stake in three companies which hold three office buildings in Germany through a share deal. The total consideration paid in cash amounted to EUR 104 million, out of which EUR 65 million was already paid in 2018. The acquisition was treated as an asset acquisition in which the company acquired investment property of EUR 152 million and bank loans amounting to EUR 52 million and working capital for amount of EUR 4 million." — Vivion 1H 2019 financial statements, p. 19"

"So I just wanted to highlight that to refresh everyone's sort of memories on what we said, what we have done, and sort of what we're focused on sort of moving forward. But I think post WCA, there's not another larger scale opportunity that's in our horizon at the moment, and we're just going to focus on getting these integrated properly and then focusing on tucking-in smaller M&A deals like what we've talked about acquiring sort of 25 to 30 deals a year of sort of $1 to $10m of EBITDA. — GFL CEO Dovigi, Aug 13, 2020"

""Our view on capital is that it's not our capital. This capital belongs to shareholders both the capital in the form of debt and equity and we like the discipline of coming to the market when the capital investments exceed that of our cash flow." — CEO Jay Brown, July 2017; "We've invested in fiber because we think it enhances long-term dividends per share. And that's the measure upon which we make all of our discretionary capital investments, whether it's in towers or on the fiber side." — CEO Jay Brown, April 2018"

""...we left money on the table. For example, our staffing levels were not optimized given the reduced attendance in the first half..." — Selim Bassoul, CEO, Six Flags (NYSE: SIX), Q2 2022 SIX Earnings Conference Call, August 11th, 2022; "...the sustained improvements we are seeing in guest satisfaction and spending per capita and our improved October results give me confidence we are moving in the right direction." — Selim Bassoul, CEO, Six Flags (NYSE: SIX), Q3 2022 SIX Earnings Conference Call, November 10th, 2022"